Vanguard Group Inc. Buys 1,846 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Vanguard Group Inc. lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 0.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,580,117 shares of the medical instruments supplier’s stock after acquiring an additional 1,846 shares during the quarter. Vanguard Group Inc. owned approximately 0.07% of LeMaitre Vascular worth $145,592,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in LMAT. Raymond James Financial Inc. purchased a new position in LeMaitre Vascular during the fourth quarter worth about $14,900,000. Barclays PLC lifted its position in shares of LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after buying an additional 29,180 shares in the last quarter. State Street Corp boosted its stake in shares of LeMaitre Vascular by 3.6% in the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock worth $76,363,000 after buying an additional 28,525 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in shares of LeMaitre Vascular by 31.8% in the fourth quarter. Teacher Retirement System of Texas now owns 101,851 shares of the medical instruments supplier’s stock valued at $9,385,000 after acquiring an additional 24,586 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of LeMaitre Vascular by 4.5% during the third quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier’s stock valued at $50,403,000 after acquiring an additional 23,443 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Insiders Place Their Bets

In other news, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now directly owns 5,564 shares of the company’s stock, valued at approximately $456,915.68. This represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Stock Down 0.5 %

Shares of NASDAQ:LMAT opened at $79.39 on Tuesday. The firm has a market capitalization of $1.79 billion, a PE ratio of 43.38, a P/E/G ratio of 2.22 and a beta of 0.89. The company has a 50-day moving average price of $91.22 and a two-hundred day moving average price of $94.15. LeMaitre Vascular, Inc. has a twelve month low of $62.39 and a twelve month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.49. The business had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. Analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were issued a dividend of $0.20 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. The ex-dividend date of this dividend was Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a yield of 1.01%. LeMaitre Vascular’s dividend payout ratio is 41.24%.

Analyst Upgrades and Downgrades

LMAT has been the topic of several research analyst reports. Lake Street Capital boosted their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price target on the stock. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Finally, StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $95.25.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.